Label: GLYCOPYRROLATE tablet
- NDC Code(s): 50268-363-11, 50268-363-15
- Packager: AvPAK
- This is a repackaged label.
- Source NDC Code(s): 13107-014
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Updated May 16, 2022
If you are a consumer or patient please visit this version.
Glycopyrrolate tablets, USP contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide .
Each 1 mg tablet contains:
Glycopyrrolate, USP......... 1 mg
Each 2 mg tablet contains:
Glycopyrrolate, USP..........2 mg
Inactive Ingredients: dibasic calcium phosphate dihydrate, lactose monohydrate, magnesium Stearate, povidone, and sodium starch glycolate.
Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.
Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.
The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.
- INDICATIONS AND USAGE
Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.
In the presence of a high environmental temperature, heatprostration (fever and heat stroke due to decreased sweating) can occur with use of glycopyrrolate tablets.
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.
Glycopyrrolate tablets may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.
Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.
The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.
It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.
Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.
Use glycopyrrolate tablets with caution in the elderly and in all patients with:
- Autonomic neuropathy.
- Hepatic or renal disease.
- Ulcerative colitis–large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate “toxic megacolon,” a serious complication of the disease.
- Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.
- Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.
Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.
Glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.
To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email email@example.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.
- To guard against further absorption of the drug–use gastric lavage, cathartics and/or enemas.
- To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.)–utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
- To combat hypotension–use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
- To combat respiratory depression–administer oxygen; utilize a respiratory stimulant such as Dopram ® i.v.; artificial respiration.
DOSAGE AND ADMINISTRATION
The dosage of glycopyrrolate tablets should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.
Glycopyrrolate tablets 1 mg. The recommended initial dosage of glycopyrrolate tablets for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms. For maintenance, a dosage of one tablet twice a day is frequently adequate.
Glycopyrrolate tablets 2 mg. The recommended dosage of glycopyrrolate tablets for adults is one tablet two or three times daily at equally spaced intervals.
Glycopyrrolate tablets are not recommended for use in pediatric patients under the age of 12 years.
There are no known drug interactions.
Glycopyrrolate Tablets USP, 1 mg are white to off-white, round, beveled edge uncoated tablets, debossed with 'Y' and break line on one side and '08' on the other side.
NDC 50268-363-15 (10 tablets per card, 5 cards per carton).
Glycopyrrolate Tablets USP, 2 mg are white to off-white, round, beveled edge uncoated tablets, debossed with 'Y' and break line on one side and '51' on the other side.
20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].
Keep this and all medication out of the reach of children.
Dispense in a tight container.
Trademarks are the property of their respective owners.
Pulaski, TN 38478
Mfg. Rev. 04/18
AV 03/21 (P)
- PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 mg
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:50268-363(NDC:13107-014) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength GLYCOPYRROLATE (UNII: V92SO9WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D) GLYCOPYRROLATE 1 mg Inactive Ingredients Ingredient Name Strength DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) POVIDONE (UNII: FZ989GH94E) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color white (White to Off-white) Score 2 pieces Shape ROUND (Beveled Edge) Size 8mm Flavor Imprint Code Y;08 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:50268-363-15 50 in 1 BOX 03/11/2021 1 NDC:50268-363-11 1 in 1 BLISTER PACK; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA202675 03/11/2021 Labeler - AvPAK (832926666)